

Special Issue

Advances in Cell Therapy for Leukemias

Message from the Guest Editors

Despite significant advances in frontline treatments for acute leukemia in adults, the overall prognosis remains poor, especially for high-risk groups. These patients face relapse rates close to 50%, with a five-year overall survival rate falling below 10% after standard multi-agent chemotherapy in relapse settings. Cell-based therapies are increasingly being used either as frontline or salvage treatments to improve remission rates, often serving as a bridge to stem cell transplantation once remission is achieved. The field of leukemia treatment has seen substantial progress with FDA-approved therapies such as Blinatumomab, a bispecific T-cell engager targeting CD19, and Inotuzumab Ozogamicin, an antibody-drug conjugate targeting CD22. Additionally, various cell-based therapies targeting markers like CD123, CD33, BAFR, and KMT2A rearrangements are in various stages of clinical trials. This Special Issue aims to explore the latest strategies and emerging treatment options within the field of cell therapy for leukemia.

Guest Editors

Dr. Salman Otoukesh

City of Hope National Med Center, Duarte, CA, USA

Dr. Idoroenyi U. Amanam

City of Hope National Med Center, Duarte, CA, USA

Deadline for manuscript submissions

closed (20 June 2025)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/225257

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).